The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
|Slideshows|January 22, 2020
8 questions for a thorough history to diagnose migraines
When evaluating and diagnosing migraines in pediatric patients, a thorough medical history is key to giving a diagnosis. These 8 questions are structured to pinpoint concerning headache patterns earlier in the diagnosing process.
Advertisement
Advertisement
Related to this article
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
2
HPV vaccine hesitancy and lack of school requirements may contribute to stalled coverage
3
FDA grants Breakthrough Device Designation to Glucommander Pediatrics for IV insulin dosing
4
Starting HPV vaccination earlier gives pediatricians more opportunities to protect children
5